WF
NVIV

Welch & Forbes’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Welch & Forbes’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5
Closed -$52K – 372
2018
Q1 		$52K Hold
5
– – ﹤0.01% 355
2017
Q4 		$78K Sell
5
-14
-74% -$324K ﹤0.01% 337
2017
Q3 		$504K Sell
19
-2
-10% -$61.5K 0.01% 240
2017
Q2 		$1.08M Sell
21
-6
-22% -$328K 0.03% 190
2017
Q1 		$2.06M Sell
27
-11
-29% -$889K 0.06% 162
2016
Q4 		$2.98M Sell
38
-15
-28% -$1.34M 0.09% 140
2016
Q3 		$6.82M Buy
53
+1
+2% +$125K 0.24% 98
2016
Q2 		$5.66M Buy
52
+2
+4% +$235K 0.17% 113
2016
Q1 		$6.58M Buy
50
+2
+4% +$215K 0.2% 109
2015
Q4 		$6.5M Buy
48
+7
+17% +$1.04M 0.21% 109
2015
Q3 		$6.67M Hold
41
– – 0.22% 103
2015
Q2 		$12.5M Buy
+41
New +$10.8M 0.39% 76

Other funds holding NVIV

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Welch & Forbes's NVIV Position: Q2 2018 in Review

Welch & Forbes sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2018, closing a stake of 5 shares — an estimated $52K sold.

Welch & Forbes first reported a position in NVIV in Q2 2015 and held it in 12 quarters. The position peaked at $12.5M in Q2 2015. 17 funds tracked by Wall St. Rank hold NVIV as of Q2 2018.

  • Welch & Forbes reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2018 after selling out during the quarter.
  • Welch & Forbes sold 5 InVivo Therapeutics Holdings Corp shares in Q2 2018, an estimated $52K.
  • Welch & Forbes first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 12 quarters.
  • Welch & Forbes's InVivo Therapeutics Holdings Corp position peaked at $12.5M in Q2 2015.
  • 17 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2018.

Based on Welch & Forbes's 13F filing for Q2 2018, filed 16 Jul 2018.